Scene 1

© Satya | 2. ▪
High-value, Difficult to Drug, Precision Oncology Targets. 

Scene 2

▪
High-value, Difficult to Drug, 
Precision Oncology Targets

Licensing pre-clinical stage 
programs, and Partnering of earlier 
stage programs as Integrated 
Discovery collaborations

Select list of programs selected and led to clinic
Satya: A Targeted Oncology biotech

Target
RAD51
sosi
PKMYTI
KIF18A
PARG
MoA
Disruption of HRR in ds
DNA breaks
Retain RAS in inactive
state/ EGFR mut
DDR, Synthetic lethality
Regulation of
chromosome
aggregation in high CIN
cells
Regulator of DNA repair
Indications
Breast, Ovarian & high
replication stress driven solid
tu mors
EGFR & RAS driven NSCLC, CRC
CCNEI amp, FBXW7 loss
m arked solid tum ors
CIN-high TNBC & CRC
Rights
GI obal;
PCT filed
GI obal;
PCT filed
GI obal;
Prov. filed
GI obal
GI obal
Hit Gen
Hit-Lead
Lead-
Op
IND
studies
To be
initiated
To be
initiated
HRD driven Breast, Ovarian
through hydrolysis in
can cers
PARP
Additional targets in validation

Scene 3

pproved drug
Glenmapk
A new way for a new world
LUPIN
*Rhizen
Pharmaceuticals AG
Daiichi-Sankyo
AURIGENE
Accelerating Discovery
IIMB
O Satya | 3

Select list of programs selected and led to clinic

Team 
- led > 25 programs to clinic, including one approved drug

Sukanya Patra,
Director, Biology
Navnath P. Karche, 
Director Chemistry

Roychowdhary, 
Formerly Sr VP 
Oncology, Sanofi

Scene 4

RAD51 represents a first-in-class opportunity in the DDR space

Satya’s compound focuses on a unique MoA, leading to higher cellular 
activity compared to other DDR targets, but with potentially lower safety 
concerns

Satya’s best in class compound has better PD compared to competitors,  
resulting in better efficacy

rose

Page 1 (0s)

Page 2 (8s)

Page 3 (38s)

Page 4 (1m 10s)

Page 5 (1m 50s)